In 2017, after previous appointments at Washington University and the Sanford Burnham Prebys Medical Discovery Institute, Dr. Kelly moved to the University of Pennsylvania where he was named Director of the Pennsylvania Cardiovascular Institute. Dr. Kelly’s research interests stem from an early fascination with rare inborn errors in mitochondrial metabolism that cause sudden death and heart failure. His laboratory has identified molecular switches that define distinct forms of heart failure, a key step towards identifying therapeutic targets for phenotype-specific treatment of heart failure. More recently, the Kelly laboratory uses proteomic and metabolomic approaches to investigate the metabolic origins of heart failure. Dr. Kelly is an Associate Editor for the Journal of the American College of Cardiology-Basic to Translational Science. He serves, or has served, on the Editorial Boards of The Journal of Clinical Investigation, Genes & Development, Nuclear Receptor Signaling, Circulation, and Circulation Research. He has held leadership advisory roles for the AHA, the NHLBI, Pfizer, and Eli Lilly. Dr. Kelly is a member of the ASCI, the American Association of Physicians, and is a recipient of the AHA Basic Research Prize.